Intrahepatic Transcriptional Signature Associated with Response to Interferon-[alpha] Treatment in the Woodchuck Model of Chronic Hepatitis B: e1005103

Recombinant interferon-alpha (IFN-[alpha] ) is an approved therapy for chronic hepatitis B (CHB), but the molecular basis of treatment response remains to be determined. The woodchuck model of chronic hepatitis B virus (HBV) infection displays many characteristics of human disease and has been extensively used to evaluate antiviral therapeutics. In this study, woodchucks with chronic woodchuck hepatitis virus (WHV) infection were treated with recombinant woodchuck IFN-[alpha] (wIFN-[alpha] ) or placebo (n = 12/group) for 15 weeks. Treatment with wIFN-[alpha] strongly reduced viral markers in the serum and liver in a subset of animals, with viral rebound typically being observed following cessation of treatment. To define the intrahepatic cellular and molecular characteristics of the antiviral response to wIFN-[alpha] , we characterized the transcriptional profiles of liver biopsies taken from animals (n = 8-12/group) at various times during the study. Unexpectedly, this revealed that the antiviral response to treatment did not correlate with intrahepatic induction of the majority of IFN-stimulated genes (ISGs) by wIFN-[alpha] . Instead, treatment response was associated with the induction of an NK/T cell signature in the liver, as well as an intrahepatic IFN-[gamma] transcriptional response and elevation of liver injury biomarkers. Collectively, these data suggest that NK/T cell cytolytic and non-cytolytic mechanisms mediate the antiviral response to wIFN-[alpha] treatment. In summary, by studying recombinant IFN-[alpha] in a fully immunocompetent animal model of CHB, we determined that the immunomodulatory effects, but not the direct antiviral activity, of this pleiotropic cytokine are most closely correlated with treatment response. This has important implications for the rational design of new therapeutics for the treatment of CHB.